Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06459024Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT02917720Phase 2Active Not Recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

Role: lead

NCT01596114Phase 3Completed

European Stop Tyrosine Kinase Inhibitor Study

Role: lead

All 3 trials loaded